Oppenheimer & Co’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Oppenheimer & Co’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-37,950	Closed	-$56.9K	–	1504
2023 Q1	$56.9K	Hold	37,950	–	–	﹤0.01%	1341
2022 Q4	$37.9K	Sell	37,950 -1,000	-3%	-$1.35K	﹤0.01%	1324
2022 Q3	$70K	Buy	38,950 +1,300	+3%	+$3.77K	﹤0.01%	1315
2022 Q2	$109K	Hold	37,650	–	–	﹤0.01%	1331
2022 Q1	$104K	Sell	37,650 -7,700	-17%	-$24.2K	﹤0.01%	1413
2021 Q4	$211K	Sell	45,350 -3,350	-7%	-$20.9K	﹤0.01%	1382
2021 Q3	$414K	Buy	+48,700	New	+$688K	0.01%	1095

Oppenheimer & Co's TCRR Position: Q2 2023 in Review

Oppenheimer & Co sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 37,950 shares — an estimated $56.9K sold.

Oppenheimer & Co first reported a position in TCRR in Q3 2021 and held it in 7 quarters. The position peaked at $414K in Q3 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Oppenheimer & Co reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Oppenheimer & Co sold 37,950 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $56.9K.
Oppenheimer & Co first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Oppenheimer & Co's TCR2 Therapeutics Inc. Common Stock position peaked at $414K in Q3 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Oppenheimer & Co's 13F filing for Q2 2023, filed 3 Aug 2023.